Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RAR-Immune: Nivolumab + Ipilimumab vs Pazopanib in Rare Advanced Sarcomas
2020-002821-28Phase 3Active
- Sponsor
- Centre Léon Bérard
- Start
- Oct 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial in Bone and soft tissue sarcoma comparing Nivolumab + Ipilimumab with Pazopanib (2 arms). Primary endpoint: Progression-Free Survival. Started Oct 2020; status: active.
02
Drugs
03
Conditions
Bone and soft tissue sarcoma
Beyond the preview
Go deeper on 2020-002821-28.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-002821-28.